Loomis Sayles & Co. L P Sells 5,724 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Loomis Sayles & Co. L P cut its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 3.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 178,899 shares of the biotechnology company’s stock after selling 5,724 shares during the quarter. Loomis Sayles & Co. L P owned about 0.29% of Ascendis Pharma A/S worth $24,629,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Wilmington Savings Fund Society FSB bought a new position in shares of Ascendis Pharma A/S in the 3rd quarter worth $30,000. Jones Financial Companies Lllp boosted its holdings in Ascendis Pharma A/S by 394.0% during the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock worth $34,000 after buying an additional 197 shares during the last quarter. Blue Trust Inc. grew its position in shares of Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock worth $56,000 after buying an additional 328 shares during the period. Groupama Asset Managment bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter valued at about $60,000. Finally, GAMMA Investing LLC raised its position in shares of Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 214 shares during the period.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND opened at $154.68 on Friday. The stock has a market capitalization of $9.39 billion, a PE ratio of -21.79 and a beta of 0.62. The company’s 50-day moving average price is $144.16 and its two-hundred day moving average price is $137.01. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.64. On average, analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Morgan Stanley set a $180.00 target price on shares of Ascendis Pharma A/S in a research note on Tuesday, February 18th. Cantor Fitzgerald raised their price objective on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 25th. JPMorgan Chase & Co. boosted their target price on Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an “overweight” rating in a research note on Tuesday, March 18th. UBS Group started coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a “buy” rating and a $196.00 price target on the stock. Finally, Evercore ISI increased their target price on Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 18th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and a consensus price target of $204.64.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.